Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

Pfizer Inc. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Wednesday, March 4, 2026. Michael Nagle | Bloomberg | Getty ImagesPfizer on Tuesday reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing an added $1.5 billion in sales from its non-Covid products. The company is now expecting full-year revenue to total $60.5 billion to $62.5 billion, which compares to a previous outlook of $59.5 billion to $62.5 billion. That sales range would still be roughly flat or down slightly compared with 2025 revenue of $62.6 billion.Pfizer said it cut its full-year revenue expectation for its Covid products – the vaccine and antiviral pill Paxlovid – to $4 billion, down from around $5 billion previously. The pharmaceutical giant reiterated its full-year adjusted profit outlook of between $2.80 and $3 per share. Here's what the company reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: 77 cents adjusted vs. 68 cents expectedRevenue: $15.03 billion vs. $14.41 billion expectedPfizer reported revenue of $15.03 billion for the first q...